Phase 3 Trail of 117 Lu-Dotatate for Midgut Neuroendocrine Tumors

BACKGROUND:

Patients with advanced midgut neuroendocrine tumors who have had disease progression during first-line somatostatin analogue therapy have limited therapeutic options. This randomized, controlled trail evaluated the efficacy and safety of lutetium-177 (177Lu)-Dotatate in patients with advanced, progressive, somatostatin-receptor-positive midgut neuroendocrine tumors.

Auteurs: Baum RP, Benson A, Berlin J, Bushnell D, Caplin M, Chasen B, Delpassand E, El-Haddad G, Erion JL, Grande E, Hendifar A, Hobday T, Jacene H, Krenning EP, Kulkarni HR, Kulke MH, Kunz PL, Kwekkeboom DJ, Lebtahi R, Lopera Sierra M, Mittra E, Mora J, O'Dorisio TM, Öberg K, Pavel ME, Reed N, Ruszniewski P, Santoro P, Seregni E, Srirajaskanthan R, Strosberg J, Thevenet T, Van Cutsem E, Wolin E, Yao J
Categorieën: NET Kanker